pozanicline has been researched along with Substance Withdrawal Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blendy, JA; Turner, JR; Yohn, NL | 1 |
| Connor, DA; Gould, TJ; Yildirim, E | 1 |
2 other study(ies) available for pozanicline and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Drug Partial Agonism; Indoles; Male; Mice; Nicotine; Nicotinic Agonists; Pyridines; Pyrrolidines; Quinuclidines; Radioligand Assay; Receptors, Nicotinic; Substance Withdrawal Syndrome; Time Factors; Up-Regulation | 2014 |
ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.
Topics: Animals; Cognition; Conditioning, Psychological; Cues; Dose-Response Relationship, Drug; Drug Partial Agonism; Fear; Hippocampus; Indoles; Learning; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Pyridines; Pyrrolidines; Quinuclidines; Receptors, Nicotinic; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2015 |